BOULDER, CO -- (Marketwired) -- 05/13/14 -- Cannabis Therapy Corp. (OTCQB: CTCO) (the "Company") a development stage enterprise focused on the business of manufacturing and marketing pharmaceutical level products containing phytocannabinoids, an abundant and therapeutically active component of cannabis, for the treatment of various conditions and diseases, is pleased to announce participation at the upcoming Colorado Cannabis Summit in Denver.
This first ever B2B summit in Denver is a daylong event to be held at the Exdo Event Center on May 22nd. The event brings together participants from across a number of industry sectors, academia, government and related stakeholders in this rapidly expanding sector. Workshops and presentations will be offered with expert panelists from leading Colorado businesses and institutions. Topics include Product Testing & Safety, Regulations & Taxes, Buildings & Security and Technology Updates for Canna-business, plus Best Practices for Human Resources and Operations. To find out more about the summit visit: www.co-cannabis-summit.com.
Cannabis Therapy Corp President & CEO Soren Mogelsvang advises, "We are extremely pleased to have the opportunity to explore a number of opportunities this event presents. I personally intend to make myself available for one-on-one meetings and invite attendees to contact us at email@example.com to arrange times. This summit brings together a regional level of interest, expertise and community that we are very interested in becoming a big part of."
In related news, the Company wishes to advise that it has released a corporate video detailing its business approach and strategic goals which can be viewed on its website at: http://cannabistherapy.com/news/presentations/.
Additional details of the Company's business, finances, appointments and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer with the Securities and Exchange Commission ("SEC") available at www.sec.gov.
About Cannabis Therapy Corp. (OTCQB: CTCO)
Cannabis Therapy Corp. aims to develop and market safe, phytocannabinoid-based medicinal products and to apply rigorous manufacturing and quality control standards to become a global leader in the research, development, manufacturing, testing and marketing of cannabinoid ingredients and therapies. For more information visit www.cannabistherapy.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the availability of additional funding; and the Company's business, product development, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's current reports on Form 8-K. The Company does not undertake to update these forward-looking statements.
ON BEHALF OF THE BOARD,
Soren Mogelsvang, President & CEO
Cannabis Therapy Corp.